{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:41:26Z","timestamp":1790912486911,"version":"4.1.0"},"reference-count":61,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2017.00863","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T23:45:19Z","timestamp":1501803919000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Clinical Efficacy, Safety, and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) in Children: A Systematic Review with Meta-analysis"],"prefix":"10.3389","volume":"8","author":[{"given":"Moffat","family":"Malisheni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana F.","family":"Khaiboullina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert A.","family":"Rizvanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Takah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Murewanhema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1089\/vim.2014.0093","article-title":"Dengue vaccine development: strategies and challenges","volume":"28","author":"Ramakrishnan","year":"2015","journal-title":"Viral Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1590\/S1020-49892006001100007","article-title":"Dengue in the Americas and Southeast Asia: do they differ?","volume":"20","author":"Halstead","year":"2006","journal-title":"Rev Panam Salud Publica"},{"key":"B3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/QCO.0b013e32835fb938","article-title":"The pathogenesis of dengue","volume":"26","author":"Yacoub","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e1760","DOI":"10.1371\/journal.pntd.0001760","article-title":"Refining the global spatial limits of dengue virus transmission by evidence-based consensus","volume":"6","author":"Brady","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.biotechadv.2010.11.008","article-title":"Review of dengue virus and the development of a vaccine","volume":"29","author":"Murrell","year":"2011","journal-title":"Biotechnol Adv"},{"key":"B7","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","article-title":"Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses","volume":"28","author":"Guy","year":"2010","journal-title":"Vaccine"},{"key":"B8","unstructured":"Global Strategy for Dengue Prevention and Control 2012\u201320202012"},{"key":"B9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"B10","unstructured":"Dengue and Severe Dengue2015"},{"key":"B11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nri3916","article-title":"New insights into the immunopathology and control of dengue virus infection","volume":"15","author":"Screaton","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cimid.2007.05.010","article-title":"Dengue hemorrhagic fever with special emphasis on immunopathogenesis","volume":"30","author":"Kurane","year":"2007","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1007\/s11033-010-0488-1","article-title":"A molecular evaluation of dengue virus pathogenesis and its latest vaccine strategies","volume":"38","author":"Faheem","year":"2011","journal-title":"Mol Biol Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/QCO.0b013e328329ae32","article-title":"Pathogenesis and prevention of dengue virus infection: state-of-the-art","volume":"22","author":"Tan","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"B15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/B978-0-12-800098-4.00007-6","article-title":"Dengue virus vaccine development","volume":"88","author":"Yauch","year":"2014","journal-title":"Adv Virus Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1016\/j.vaccine.2014.07.008","article-title":"Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: a meta-analysis of randomized trials","volume":"32","author":"da Costa","year":"2014","journal-title":"Vaccine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1136\/bmj.b2535","article-title":"Reprint \u2013 preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"89","author":"Moher","year":"2009","journal-title":"Phys Ther"},{"key":"B21","unstructured":"123Convention on the Rights of the Child1989"},{"key":"B22","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/S1386-6532(09)70287-2","article-title":"Guidelines for clinical trials of dengue vaccine in endemic areas","volume":"46","author":"Hombach","year":"2009","journal-title":"J Clin Virol"},{"key":"B23","unstructured":"Glossary of terms used in pharmacovigilance16WHO Program Int Drug Monit2013"},{"key":"B24","first-page":"26","volume-title":"Guidelines for Plaque Reduction Neutralization Testing of Human Antibodies to Dengue Viruses","year":"2007"},{"key":"B25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/2046-4053-3-77","article-title":"Routine piloting in systematic reviews \u2013 a modified approach?","volume":"3","author":"Long","year":"2014","journal-title":"Syst Rev"},{"key":"B26","volume-title":"Basic Epidemiology","author":"Bonita","year":"2006"},{"key":"B27","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2011"},{"key":"B28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol Methods"},{"key":"B29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/9780470743386.ch13","article-title":"Fixed-effect versus random-effects models","volume-title":"Introduction to Meta-Analysis","author":"Borenstein","year":"2009"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.4161\/hv.26189","article-title":"Human vaccines & immunotherapeutics: news","volume":"9","author":"Riedmann","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"B31","first-page":"99","article-title":"Safety and infectivity of tetravalent Chimeric live attenuated dengue vaccine in different age populations in endemic and non-endemic areas","volume":"77","author":"Morrison","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"B32","first-page":"113","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in flavivirus-naive and -immune pediatric populations with two vaccination regimens","volume":"81","author":"Crevat","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"B33","first-page":"114","article-title":"Safety and immunogenicity in children and adults from endemic countries and adults from nonendemic countries of a tetravalent, live attenuated dengue vaccine","volume":"79","author":"Bouckenooghe","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"B34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/01.inf.0000109289.55856.27","article-title":"Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children","volume":"23","author":"Sabchareon","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1097\/INF.0b013e3181fe05af","article-title":"Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity","volume":"30","author":"Poo","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1016\/j.vaccine.2011.03.057","article-title":"Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines","volume":"29","author":"Capeding","year":"2011","journal-title":"Vaccine"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.4269\/ajtmh.13-0304","article-title":"Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil","volume":"89","author":"Dayan","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.4161\/hv.21224","article-title":"Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45: phase II randomized controlled trial in Singapore","volume":"8","author":"Leo","year":"2012","journal-title":"Hum Vaccines Immunother"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2157-7560.1000162","article-title":"Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children","volume":"3","author":"Tran","year":"2012","journal-title":"J Vaccines Vaccin"},{"key":"B40","doi-asserted-by":"publisher","first-page":"5814","DOI":"10.1016\/j.vaccine.2013.10.013","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, phase III study","volume":"31","author":"Amar-Singh","year":"2013","journal-title":"Vaccine"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1097\/INF.0b013e31829b8022","article-title":"Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds a randomized, controlled, phase II trial in Latin America","volume":"32","author":"Villar","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"5935","DOI":"10.1016\/j.vaccine.2012.07.043","article-title":"Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru","volume":"30","author":"Lanata","year":"2012","journal-title":"Vaccine"},{"key":"B43","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1097\/INF.0000000000000752","article-title":"First experience of concomitant vaccination against dengue and MMR in toddlers","volume":"34","author":"Crevat","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1086\/517587","article-title":"Dengue virus evolution and virulence models","volume":"44","author":"Hesse","year":"2007","journal-title":"Clin Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41182-016-0004-y","article-title":"Human antibody response to dengue virus: implications for dengue vaccine design","volume":"44","author":"Moi","year":"2016","journal-title":"Trop Med Health"},{"key":"B46","doi-asserted-by":"publisher","first-page":"S334","DOI":"10.1016\/j.amepre.2015.09.006","article-title":"Trials and tribulations on the path to developing a dengue vaccine","volume":"49","author":"Thomas","year":"2015","journal-title":"Am J Prev Med"},{"key":"B47","first-page":"96","article-title":"Molecular evolution of dengue type 2 virus in Thailand","volume":"58","author":"Haven","year":"1998","journal-title":"Trop Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.mjafi.2014.09.011","article-title":"Discovery of fifth serotype of dengue virus (denv-5): a new public health dilemma in dengue control","volume":"71","author":"Mustafa","year":"2015","journal-title":"Med J Armed Forces India"},{"key":"B49","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1136\/pgmj.2004.019638","article-title":"Dengue viral infections","volume":"80","author":"Malavige","year":"2004","journal-title":"Postgrad Med J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e1000821","DOI":"10.1371\/journal.ppat.1000821","article-title":"Natural strain variation and antibody neutralization of dengue serotype 3 viruses","volume":"6","author":"Wahala","year":"2010","journal-title":"PLoS Pathog"},{"key":"B51","unstructured":"14Questions and Answers: Vaccine Effectiveness Estimates for Seasonal Influenza Vaccines2015"},{"key":"B52","first-page":"421","volume-title":"Safety of CYD-TDV Dengue Vaccine: Weekly Epidemiological Record","year":"2016"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa1503877","article-title":"Symptomatic dengue in children in 10 Asian and Latin American countries","volume":"374","author":"L\u2019Azou","year":"2016","journal-title":"N Engl J Med"},{"key":"B54","first-page":"160","article-title":"Dengue: guidelines for diagnosis, treatment, prevention and control","volume":"409","year":"2009","journal-title":"Prev Control"},{"key":"B55","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1586\/eri.12.76","article-title":"Diagnosis of dengue: an update","volume":"10","author":"Tang","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B56","doi-asserted-by":"publisher","first-page":"825","DOI":"10.4269\/ajtmh.2009.08-0625","article-title":"Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: how alterations in assay conditions impact performance","volume":"81","author":"Thomas","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"B57","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/1471-2334-12-233","article-title":"Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis","volume":"12","author":"Rainwater-Lovett","year":"2012","journal-title":"BMC Infect Dis"},{"key":"B58","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3389\/fimmu.2014.00183","article-title":"Human immune responses to dengue virus infection: lessons learned from prospective cohort studies","volume":"5","author":"Endy","year":"2014","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"962","DOI":"10.4269\/ajtmh.12-0461","article-title":"Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development","volume":"88","author":"Timiryasova","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"B60","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1586\/14760584.2013.824712","article-title":"Challenges in reducing dengue burden; diagnostics, control measures and vaccines","volume":"12","author":"Lam","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.3201\/eid1708.101515","article-title":"Dengue virus infection in Africa","volume":"17","author":"Amarasinghe","year":"2011","journal-title":"Emerg Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00863\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T23:45:40Z","timestamp":1501803940000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00863\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,4]]},"references-count":61,"alternative-id":["10.3389\/fimmu.2017.00863"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2017.00863","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,4]]},"article-number":"863"}}